Giulia De Napoli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Giulia De Napoli has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Chiara Baldovini
Department of Pathology, Cardiovascular and Cardiac Transplant Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
1 shared publication- Diana Ferraro
Dipartimento di Neuroscienze, Ospedale Civile di Baggiovara, Azienda Ospedaliera-Università di Modena, Modena, Italy
1 shared publication Enrico Gotti
Cardiology Unit, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy
1 shared publicationFrancesca Vitetta
Neurology Unit, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy
1 shared publicationKrzysztof Smolik
Department of Biomedical, Metabolic and Neurosciences, University of Modena and Reggio Emilia, Modena, Italy
1 shared publicationLuisa Di Sciascio
Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
1 shared publication
Latest Publications
- 31 December 2025
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (9) , 985-988
Cardiogenic shock after ocrelizumab infusion in relapsing-remitting multiple sclerosis
A 42-year-old man with relapsing-remitting multiple sclerosis and no prior cardiac history developed a severe but reversible left ventricular systolic dysfunction following ocrelizumab administration. Symptoms started 24–36 hours after the infusion and worsened over 10 days. A thorough diagnostic evaluation, including blood tests, coronary artery angiography, cardiac magnetic resonance imaging, and endomyocardial biopsy excluded ischemic or infectious causes of myocardial damage. Although cardiac complications have not previously been reported with ocrelizumab, this case suggests the drug may rarely cause reversible severe cardiac dysfunction and highlights the importance of vigilance for cardiotoxicity in people with multiple sclerosis.
- 31 December 2025
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (9) , 985-988
Cardiogenic shock after ocrelizumab infusion in relapsing-remitting multiple sclerosis
A 42-year-old man with relapsing-remitting multiple sclerosis and no prior cardiac history developed a severe but reversible left ventricular systolic dysfunction following ocrelizumab administration. Symptoms started 24–36 hours after the infusion and worsened over 10 days. A thorough diagnostic evaluation, including blood tests, coronary artery angiography, cardiac magnetic resonance imaging, and endomyocardial biopsy excluded ischemic or infectious causes of myocardial damage. Although cardiac complications have not previously been reported with ocrelizumab, this case suggests the drug may rarely cause reversible severe cardiac dysfunction and highlights the importance of vigilance for cardiotoxicity in people with multiple sclerosis.